<![CDATA[Preeclampsia remains a leading cause of maternal morbidity and mortality, particularly in low-resource settings where access to early screening tools is limited. Urinary miRNA-1-3p have emerged as promising biomarkers for preeclampsia due to their stability in maternal urine during the first trimester, weeks before the onset of clinical symptoms. It reflects early molecular and pathological changes in preeclampsia. Recent advances in nanotechnology have improved miRNA detection using electrochemical biosensors that are suitable for POC testing. The incorporation of gold nanoparticles, further enhances biosensor performance. This study aims to describe the potential of this novel biosensor for detecting miRNA-1-3p in maternal urine as an early antenatal screening tool for preeclampsia. There was elevated levels of miRNA 1-3p in maternal urine during first trimester in women with PE with p value 0.035, showing its potential as non-invasive biomarkers. This biosensor can detect miRNA 1-3p through probe hybridization and produces a measurable electrochemical signal. The incorporation of gold nanoparticles significantly enhances the biosensor sensitivity by about 80% by increasing electroactive surface area and enabling the detection of very low miRNA concentrations with low LOD by about 0.35 fM. Moreover, the gold nanoparticle enhance the biosensor specifity by reducing non-specific binding. This novel biosensor offers non-invasive, rapid, low cost, and portable tool, making it suitable for POC testing in low resource settings. This novel biosensor has strong potential to become a transformative as an early antenatal screening tool for preeclampsia in low-resource settings, may contribute to better maternal health outcomes. ]]>
